UCN-02 is primarily investigated for its potential in cancer therapy due to its ability to inhibit specific kinases involved in cell cycle regulation. It has shown promise in preclinical studies for targeting tumor cells, particularly in enhancing the efficacy of other chemotherapeutic agents. Researchers are exploring its role in overcoming drug resistance in certain cancers, making it a candidate for combination therapies. Additionally, UCN-02 is being studied for its neuroprotective properties, potentially aiding in the treatment of neurodegenerative diseases by modulating cellular stress responses. Its application in these areas remains under active research to fully understand its therapeutic potential.